Lung function and cardiovascular disease: a two-sample Mendelian randomisation study.


Journal

The European respiratory journal
ISSN: 1399-3003
Titre abrégé: Eur Respir J
Pays: England
ID NLM: 8803460

Informations de publication

Date de publication:
09 2021
Historique:
received: 18 08 2020
accepted: 21 01 2021
pubmed: 13 2 2021
medline: 28 10 2021
entrez: 12 2 2021
Statut: epublish

Résumé

Observational studies suggest an association between reduced lung function and risk of coronary artery disease and ischaemic stroke, independent of shared cardiovascular risk factors such as cigarette smoking. We use the latest genetic epidemiological methods to determine whether impaired lung function is causally associated with an increased risk of cardiovascular disease. Mendelian randomisation uses genetic variants as instrumental variables to investigate causation. Preliminary analysis used two-sample Mendelian randomisation with lung function single nucleotide polymorphisms. To avoid collider bias, the main analysis used single nucleotide polymorphisms for lung function identified from UKBiobank in a multivariable Mendelian randomisation model conditioning for height, body mass index and smoking.Multivariable Mendelian randomisation shows strong evidence that reduced forced vital capacity (FVC) causes increased risk of coronary artery disease (OR 1.32, 95% CI 1.19-1.46 per standard deviation). Reduced forced expiratory volume in 1 s (FEV There is strong evidence that reduced FVC is independently and causally associated with coronary artery disease. Although the mechanism remains unclear, FVC could be taken into consideration when assessing cardiovascular risk and considered a potential target for reducing cardiovascular events. FEV

Sections du résumé

BACKGROUND
Observational studies suggest an association between reduced lung function and risk of coronary artery disease and ischaemic stroke, independent of shared cardiovascular risk factors such as cigarette smoking. We use the latest genetic epidemiological methods to determine whether impaired lung function is causally associated with an increased risk of cardiovascular disease.
METHODS AND FINDINGS
Mendelian randomisation uses genetic variants as instrumental variables to investigate causation. Preliminary analysis used two-sample Mendelian randomisation with lung function single nucleotide polymorphisms. To avoid collider bias, the main analysis used single nucleotide polymorphisms for lung function identified from UKBiobank in a multivariable Mendelian randomisation model conditioning for height, body mass index and smoking.Multivariable Mendelian randomisation shows strong evidence that reduced forced vital capacity (FVC) causes increased risk of coronary artery disease (OR 1.32, 95% CI 1.19-1.46 per standard deviation). Reduced forced expiratory volume in 1 s (FEV
CONCLUSION
There is strong evidence that reduced FVC is independently and causally associated with coronary artery disease. Although the mechanism remains unclear, FVC could be taken into consideration when assessing cardiovascular risk and considered a potential target for reducing cardiovascular events. FEV

Identifiants

pubmed: 33574079
pii: 13993003.03196-2020
doi: 10.1183/13993003.03196-2020
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Medical Research Council
ID : MC_UU_00011/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00011/2
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/T005114/1
Pays : United Kingdom

Informations de copyright

Copyright ©The authors 2021. For reproduction rights and permissions contact permissions@ersnet.org.

Déclaration de conflit d'intérêts

Conflict of interest: D.H. Higbee has nothing to disclose. Conflict of interest: R. Granell has nothing to disclose. Conflict of interest: E. Sanderson has nothing to disclose. Conflict of interest: G. Davey Smith has nothing to disclose. Conflict of interest: J.W. Dodd has nothing to disclose.

Auteurs

Daniel H Higbee (DH)

MRC Integrative Epidemiology Unit (IEU), University of Bristol, Bristol, UK.
Academic Respiratory Unit, University of Bristol, Southmead Hospital, Bristol, UK.

Raquel Granell (R)

MRC Integrative Epidemiology Unit (IEU), University of Bristol, Bristol, UK.

Eleanor Sanderson (E)

MRC Integrative Epidemiology Unit (IEU), University of Bristol, Bristol, UK.

George Davey Smith (G)

MRC Integrative Epidemiology Unit (IEU), University of Bristol, Bristol, UK.

James W Dodd (JW)

MRC Integrative Epidemiology Unit (IEU), University of Bristol, Bristol, UK James.dodd@bristol.ac.uk).
Academic Respiratory Unit, University of Bristol, Southmead Hospital, Bristol, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH